Octreotide

Endocrinology

Acromegaly

Somatostatin

Drug

Internal medicine

Pharmacology

Hormone

Growth hormone

Medicine

European Journal of Endocrinology

Octreotide remains 40 years after its development a drug, which is commonly used in the treatment of acromegaly and GEP-NETs. Very little innovation that competes with this drug occurred over this period. This review discusses several aspects of 40 years of clinical use of octreotide, including the application of radiolabeled forms of the peptide.

ANNIVERSARY REVIEW: Octreotide, 40 years later